Daily Newsletter

15 August 2023

Daily Newsletter

15 August 2023

GE HealthCare’s wireless patient monitoring device secures FDA clearance

The vital signs measuring device gives a window into patient’s health and spots deterioration early.

Robert Barrie August 15 2023

Patients walking on hospital wards could soon be fitted with GE HealthCare’s wireless continuous monitoring solution, after the US Food and Drug Administration (FDA) granted 510(k) clearance to the device.

The device, called Portrait Mobile, enables real-time continuous monitoring of patient’s vital signs such as respiration rate, oxygen saturation and pulse rate. It can alert healthcare providers to impending patient decline and enable necessary intervention.

Moving around the ward is an important part of patient recovery, especially for those who have just had an operation, but monitoring typically occurs every 4-6 hours meaning it can be hard to catch deterioration early. GE HealthCare’s device uses wireless technology that allows patients to freely move around and gives a real-time window into patient data via a phone-sized monitor.

A 2022 report by GlobalData on continuous monitoring indicated that wireless technology is a key trend driving the market. The report also classes GE HealthCare as a leader in the external continuous monitoring device space. Portrait Mobile is part of the medical device giant’s FlexAcuity patient monitoring range. 

 “It’s important for recovery that patients be able to move around freely while their vital signs are being monitored,” said Neal Sandy, general manager, monitoring solutions, GE HealthCare.

“Until Portrait Mobile, patient monitoring required that patients be tethered to their beds, limiting mobility. GE HealthCare designed Portrait Mobile with this need in mind – the advent of a small wearable, wireless inpatient monitoring solution that provides reliable monitoring to the patient's care team, while allowing for more patient freedom and flexibility during recovery, is an important advancement in acute care.”

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.